ZIOPHARM Oncology – $50 Million Offering

Boston – May 17, 2017 – ​Cooley advised ZIOPHARM Oncology in its $50 million underwritten registered direct offering of 9,708,738 shares of common stock at an offering price of $5.15 per share. Guggenheim Securities acted as sole underwriter for the offering.

ZIOPHARM Oncology, a long-time client of Cooley, trades on the NASDAQ Capital Market as "ZIOP." It is a biotechnology company employing novel gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

The Cooley team advising ZIOPHARM Oncology included Marc Recht, Josh Rottner, Courtney Thorne, Esther Cho, Chris Gerry, James Schneider, Sarah O’Loughlin, Jeremy Naylor, Mike Faber, Heidi Erlacher, Natasha Leskovsek, Fran Wheeler, Josh Kaufman, Jason Minio and Chelsea Smith.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Marc Recht Partner, Boston
Joshua Rottner Partner, Boston
Courtney Thorne Associate, Boston
Esther Cho Associate, Boston
Christopher Gerry Associate, Boston
Sarah O'Loughlin Associate, Boston
Mike Faber Senior Counsel, San Francisco
Heidi A. Erlacher Partner in Charge - Boston
Natasha Leskovsek Partner, Washington, DC
Francis Wheeler Partner, Colorado
Josh Kaufman Partner, New York
Jason Minio Senior Paralegal, Boston
Related Practices & Industries

Capital Markets Life Sciences